View Exam | PowerPak

1. The preferred treatment strategy for acute anticoagulant-associated bleeding in a patient on warfarin therapy is:

A. exogenous vitamin K B. prothrombin complex concentrate (PCC) C. andexanet alfa D. idarucizumab E. unsure

2. The mechanism of andexanet alfa as a DOAC reversal strategy is:

A. removal of clotting Factor Xa from the bloodstream B. binding to dabigatran to disable its anticoagulant effect C. direct binding to the Factor Xa inhibitors apixaban and rivaroxaban only D. direct binding to Factor Xa to prevent it from participating in the coagulation cascade E. unsure

3. Strategies for selection of a low dose (400 mg bolus, 4 mg/minute infusion) versus a high dose (800 mg bolus, 8 mg/minute infusion) of andexanet alfa are determined by:

A. which DOAC the patient took B. the timing of the patient's last DOAC dose C. the volume of distribution of the drug D. all of the above E. unsure

4. When is use of prothrombin complex concentrate (PCC) appropriate to counteract a bleeding event in a patient receiving a direct oral anticoagulant (DOAC)?

A. PCC were used prior to the approval of a targeted DOAC reversal agent but are no longer the preferred method B. PCC can be used as an adjunct to targeted DOAC reversal agents if the bleeding event is not reversed C. PCC is indicated for reversal of dabigatran but not for Factor Xa inhibitors D. PCCs are no longer recommend for treating bleeding events in patients on DOACs or warfarin E. Unsure

5. The role of idarucizumab in the management of anticoagulant-associated bleeding is:

A. Direct binding to all DOACs (Factor Xa inhibitors and dabigatran) to treat acute bleeding and allow for urgent surgical intervention B. Direct binding to Factor Xa inhibitors, as a reversal and preventive approach for bleeding complications C. Direct binding to dabigatran to reverse the anticoagulant effect, for management of acute bleeding events and in preparation for surgical procedures D. Reversal of dabigatran for urgent surgical procedures, but not to reverse a E. Unsure

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The preferred treatment strategy for acute anticoagulant-associated bleeding in a patient on warfarin therapy is:

2. The mechanism of andexanet alfa as a DOAC reversal strategy is:

3. Strategies for selection of a low dose (400 mg bolus, 4 mg/minute infusion) versus a high dose (800 mg bolus, 8 mg/minute infusion) of andexanet alfa are determined by:

4. When is use of prothrombin complex concentrate (PCC) appropriate to counteract a bleeding event in a patient receiving a direct oral anticoagulant (DOAC)?

5. The role of idarucizumab in the management of anticoagulant-associated bleeding is:

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The preferred treatment strategy for acute anticoagulant-associated bleeding in a patient on warfarin therapy is:

2. The mechanism of andexanet alfa as a DOAC reversal strategy is:

3. Strategies for selection of a low dose (400 mg bolus, 4 mg/minute infusion) versus a high dose (800 mg bolus, 8 mg/minute infusion) of andexanet alfa are determined by:

4. When is use of prothrombin complex concentrate (PCC) appropriate to counteract a bleeding event in a patient receiving a direct oral anticoagulant (DOAC)?

5. The role of idarucizumab in the management of anticoagulant-associated bleeding is:

« Return to Activity

Customers who Purchased
this Activity also Purchased